1. Home
  2. DMAC vs ATGL Comparison

DMAC vs ATGL Comparison

Compare DMAC & ATGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMAC
  • ATGL
  • Stock Information
  • Founded
  • DMAC 2000
  • ATGL 2017
  • Country
  • DMAC United States
  • ATGL Hong Kong
  • Employees
  • DMAC N/A
  • ATGL N/A
  • Industry
  • DMAC Biotechnology: Pharmaceutical Preparations
  • ATGL
  • Sector
  • DMAC Health Care
  • ATGL
  • Exchange
  • DMAC Nasdaq
  • ATGL Nasdaq
  • Market Cap
  • DMAC 310.1M
  • ATGL 299.1M
  • IPO Year
  • DMAC N/A
  • ATGL 2023
  • Fundamental
  • Price
  • DMAC $6.97
  • ATGL $30.49
  • Analyst Decision
  • DMAC Strong Buy
  • ATGL
  • Analyst Count
  • DMAC 3
  • ATGL 0
  • Target Price
  • DMAC $12.33
  • ATGL N/A
  • AVG Volume (30 Days)
  • DMAC 443.2K
  • ATGL 14.9K
  • Earning Date
  • DMAC 11-12-2025
  • ATGL 01-01-0001
  • Dividend Yield
  • DMAC N/A
  • ATGL N/A
  • EPS Growth
  • DMAC N/A
  • ATGL N/A
  • EPS
  • DMAC N/A
  • ATGL N/A
  • Revenue
  • DMAC N/A
  • ATGL $1,590,148.00
  • Revenue This Year
  • DMAC N/A
  • ATGL N/A
  • Revenue Next Year
  • DMAC N/A
  • ATGL N/A
  • P/E Ratio
  • DMAC N/A
  • ATGL N/A
  • Revenue Growth
  • DMAC N/A
  • ATGL 42.17
  • 52 Week Low
  • DMAC $3.19
  • ATGL $1.15
  • 52 Week High
  • DMAC $7.49
  • ATGL $57.32
  • Technical
  • Relative Strength Index (RSI)
  • DMAC 66.23
  • ATGL 54.46
  • Support Level
  • DMAC $6.83
  • ATGL $28.00
  • Resistance Level
  • DMAC $7.41
  • ATGL $33.93
  • Average True Range (ATR)
  • DMAC 0.42
  • ATGL 2.72
  • MACD
  • DMAC 0.06
  • ATGL -0.18
  • Stochastic Oscillator
  • DMAC 77.88
  • ATGL 29.29

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About ATGL Alpha Technology Group Limited

Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.

Share on Social Networks: